221 related articles for article (PubMed ID: 33597075)
1. Failure of pre-exposure prophylaxis with on-demand tenofovir disoproxil fumarate/emtricitabine resulting in emergence of antiretroviral resistance.
Hsiao YY; Huang YC; Chang SY; Kuo CH; Chang SF; Lin YT; Luo YZ; Lee YL; Hung CC
J Microbiol Immunol Infect; 2021 Aug; 54(4):755-757. PubMed ID: 33597075
[No Abstract] [Full Text] [Related]
2. Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Ogbuagu O; Ruane PJ; Podzamczer D; Salazar LC; Henry K; Asmuth DM; Wohl D; Gilson R; Shao Y; Ebrahimi R; Cox S; Kintu A; Carter C; Das M; Baeten JM; Brainard DM; Whitlock G; Brunetta JM; Kronborg G; Spinner CD;
Lancet HIV; 2021 Jul; 8(7):e397-e407. PubMed ID: 34197772
[TBL] [Abstract][Full Text] [Related]
3. Failure of pre-exposure prophylaxis with daily tenofovir/emtricitabine and the scenario of delayed HIV seroconversion.
Lee SS; Anderson PL; Kwan TH; Lui GCY; Chan DPC; Wong NS; Lee KCK; Lam TTN
Int J Infect Dis; 2020 May; 94():41-43. PubMed ID: 32173577
[TBL] [Abstract][Full Text] [Related]
4. Single-agent tenofovir versus combination emtricitabine plus tenofovir for pre-exposure prophylaxis for HIV-1 acquisition: an update of data from a randomised, double-blind, phase 3 trial.
Baeten JM; Donnell D; Mugo NR; Ndase P; Thomas KK; Campbell JD; Wangisi J; Tappero JW; Bukusi EA; Cohen CR; Katabira E; Ronald A; Tumwesigye E; Were E; Fife KH; Kiarie J; Farquhar C; John-Stewart G; Kidoguchi L; Coombs RW; Hendrix C; Marzinke MA; Frenkel L; Haberer JE; Bangsberg D; Celum C;
Lancet Infect Dis; 2014 Nov; 14(11):1055-1064. PubMed ID: 25300863
[TBL] [Abstract][Full Text] [Related]
5. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
Orkin C; DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Vandercam B; de Wet J; Rockstroh J; Lazzarin A; Rijnders B; Podzamczer D; Thalme A; Stoeckle M; Porter D; Liu HC; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e195-e204. PubMed ID: 28259777
[TBL] [Abstract][Full Text] [Related]
6. Acquisition of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Infection in a Patient Taking Preexposure Prophylaxis.
Colby DJ; Kroon E; Sacdalan C; Gandhi M; Grant RM; Phanuphak P; Ananworanich J; Robb ML; Phanuphak N
Clin Infect Dis; 2018 Aug; 67(6):962-964. PubMed ID: 29961859
[TBL] [Abstract][Full Text] [Related]
7. Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
Lambert-Niclot S; Allavena C; Grude M; Flandre P; Sayon S; Andre E; Wirden M; Rodallec A; Jovelin T; Katlama C; Calvez V; Raffi F; Marcelin AG
J Antimicrob Chemother; 2016 Aug; 71(8):2248-51. PubMed ID: 27231280
[TBL] [Abstract][Full Text] [Related]
8. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study.
DeJesus E; Ramgopal M; Crofoot G; Ruane P; LaMarca A; Mills A; Martorell CT; de Wet J; Stellbrink HJ; Molina JM; Post FA; Valero IP; Porter D; Liu Y; Cheng A; Quirk E; SenGupta D; Cao H
Lancet HIV; 2017 May; 4(5):e205-e213. PubMed ID: 28259776
[TBL] [Abstract][Full Text] [Related]
9. Emtricitabine/rilpivirine/tenofovir disoproxil fumarate for the treatment of HIV-1 infection in adults.
Kabbara WK; Ramadan WH
J Infect Public Health; 2015; 8(5):409-17. PubMed ID: 26001757
[TBL] [Abstract][Full Text] [Related]
10. A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
Cottrell ML; Yang KH; Prince HM; Sykes C; White N; Malone S; Dellon ES; Madanick RD; Shaheen NJ; Hudgens MG; Wulff J; Patterson KB; Nelson JA; Kashuba AD
J Infect Dis; 2016 Jul; 214(1):55-64. PubMed ID: 26917574
[TBL] [Abstract][Full Text] [Related]
11. Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States.
Adams JL; Shelley K; Nicol MR
Pharmacotherapy; 2019 Apr; 39(4):486-500. PubMed ID: 30815960
[TBL] [Abstract][Full Text] [Related]
12. Updating the Adherence-Response for Oral Emtricitabine/Tenofovir Disoproxil Fumarate for Human Immunodeficiency Virus Pre-Exposure Prophylaxis Among Cisgender Women.
Anderson PL; Marzinke MA; Glidden DV
Clin Infect Dis; 2023 May; 76(10):1850-1853. PubMed ID: 36645796
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomised, double-blind, active-controlled phase 3 trial.
Gallant JE; Daar ES; Raffi F; Brinson C; Ruane P; DeJesus E; Johnson M; Clumeck N; Osiyemi O; Ward D; Morales-Ramirez J; Yan M; Abram ME; Plummer A; Cheng AK; Rhee MS
Lancet HIV; 2016 Apr; 3(4):e158-65. PubMed ID: 27036991
[TBL] [Abstract][Full Text] [Related]
14. Short Communication: Tenofovir Disoproxil Fumarate/Emtricitabine Fits for All as Appropriate HIV-1 Pre-Exposure Prophylaxis?
Taramasso L; Riccardi N; Del Puente F; Bruzzone B; Ripamonti D; D'Ambrosio B; Viscoli C; Di Biagio A
AIDS Res Hum Retroviruses; 2018 Feb; 34(2):168-170. PubMed ID: 29166777
[TBL] [Abstract][Full Text] [Related]
15. Single-dose pharmacokinetics and pharmacodynamics of oral tenofovir and emtricitabine in blood, saliva and rectal tissue: a sub-study of the ANRS IPERGAY trial.
Fonsart J; Saragosti S; Taouk M; Peytavin G; Bushman L; Charreau I; Hance A; Goldwirt L; Morel S; Mammano F; Loze B; Capitant C; Clavel F; Mahjoub N; Meyer L; Anderson PL; Delaugerre C; Molina JM
J Antimicrob Chemother; 2017 Feb; 72(2):478-485. PubMed ID: 28073964
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-Resistant HIV-1 Infection despite Preexposure Prophylaxis.
Knox DC; Anderson PL; Harrigan PR; Tan DH
N Engl J Med; 2017 Feb; 376(5):501-502. PubMed ID: 28146652
[No Abstract] [Full Text] [Related]
17. Brief Report: HIV-1 Evolution in Breakthrough Infections in a Human Trial of Oral Pre-exposure Prophylaxis With Emtricitabine and Tenofovir Disoproxil Fumarate.
Ruone S; Paxton L; McLaurin T; Taylor A; Hanson D; Heneine W; Brooks JT; García-Lerma JG
J Acquir Immune Defic Syndr; 2016 Jun; 72(2):129-32. PubMed ID: 26689970
[TBL] [Abstract][Full Text] [Related]
18. Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial.
Prazuck T; Verdon R; Le Moal G; Ajana F; Bernard L; Sunder S; Roncato-Saberan M; Ponscarme D; Etienne M; Viard JP; Pasdeloup T; Darasteanu I; Pialoux G; de la Blanchardière A; Avettand-Fènoël V; Parienti JJ; Hocqueloux L;
J Antimicrob Chemother; 2021 May; 76(6):1564-1572. PubMed ID: 33724373
[TBL] [Abstract][Full Text] [Related]
19. Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges.
Krakower DS; Mayer KH
Drugs; 2015 Feb; 75(3):243-51. PubMed ID: 25673022
[TBL] [Abstract][Full Text] [Related]
20. Drug Resistance During HIV Pre-Exposure Prophylaxis.
Gibas KM; van den Berg P; Powell VE; Krakower DS
Drugs; 2019 Apr; 79(6):609-619. PubMed ID: 30963509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
